Abstract Number: 0224 • ACR Convergence 2024
How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries
Background/Purpose: MRI of the sacroiliac joints (SIJs) is widely used for diagnosing and monitoring patients with spondyloarthritis (SpA). However, local radiologists might be less familiar with…Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…Abstract Number: 0851 • ACR Convergence 2024
Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…Abstract Number: 1465 • ACR Convergence 2024
The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial
Background/Purpose: Oligoarticular psoriatic arthritis (PsA, ≤4 joints affected) is common but understudied, as most clinical trials enroll patients (pts) with ≥3 swollen and tender joints.…Abstract Number: 1883 • ACR Convergence 2024
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Background/Purpose: Combined assessment of psoriatic arthritis (PsA) flare incidence and risk factors has not been conducted before, leading to challenges in effective flare management, especially…Abstract Number: 2314 • ACR Convergence 2024
Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort
Background/Purpose: Systemic inflammation is an integral part of psoriatic arthritis (PsA). Despite substantial inflammation in the affected tissues such as skin, entheses and joints, C-reactive…Abstract Number: 2331 • ACR Convergence 2024
Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can cause joint pain, swelling, and stiffness. Patients often experience flares followed by periods of remission.…Abstract Number: 2351 • ACR Convergence 2024
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Background/Purpose: Acute anterior uveitis (‘uveitis’) is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA), and incidence varies with SpA type and disease duration.1,2,3…Abstract Number: 2584 • ACR Convergence 2024
Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase…Abstract Number: 0225 • ACR Convergence 2024
Prediction of Response to Therapies and Flares Based on Ultrasound Findings at Baseline in Psoriatic Arthritis: An Analysis on a Joint Level
Background/Purpose: It is not clear how to interpret when the ultrasound and physical examination do not agree on a joint level. In this study, we…Abstract Number: 0587 • ACR Convergence 2024
Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Background/Purpose: Psoriatic arthritis (PsA) negatively impacts patients’ physical health and functional ability, which can contribute to reduced work productivity.1,2 We examined the association between achieving…Abstract Number: 0928 • ACR Convergence 2024
In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects
Background/Purpose: Interactions between fibroblast-like synoviocytes (FLSs) and macrophage-like synoviocytes (MLSs) are pivotal in the pathogenesis of RA and PsA. FLSs both activate and are activated…Abstract Number: 1296 • ACR Convergence 2024
Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times
Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…Abstract Number: 1466 • ACR Convergence 2024
Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial
Background/Purpose: Most clinical trials of Psoriatic Arthritis (PsA) exclude patients with early oligoarticular (oligo) disease and there is limited evidence to drive treatment decisions in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 81
- Next Page »